ANI Pharma

ANI Pharmaceuticals, Inc. is a bio-pharmaceutical company, which engages in developing, manufacturing, and marketing branded and generic prescription pharmaceuticals. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended release and combination products. The company was founded on August 29, 1996 and is headquartered in Baudette, MN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

ANI Pharma posts record revenues, eyes growth in Rare Disease

ANI Pharmaceuticals delivered robust financial results, showcasing strong revenue growth and EBITDA improvement. The company's focus on Rare Disease and Generics businesses, along with strategic initiatives for 2023, positions it well for continued growth. Challenges in cash flow management and cautious information sharing require attention.

ANI Pharma reports record Q1 revenues, eyes Rare Disease M&A

ANI Pharma (ANIP) delivered strong financial performance in Q1 2023, with record revenues and raised full-year guidance, driven by successful product launches and operational efficiency.
The company's focus on sustainable growth, patient care, and strategic investments in the Rare Disease space position ANI for future success.
While facing challenges such as increased operating expenses and debt obligations, ANI's strengths in revenue growth and market reception of key products provide opportunities for continued expansion.
ANI's commitment to organic deleveraging, cash generation, and potential M&A activities underscore a strategic approach to long-term growth and financial stability.

ANI Pharma reports stellar Q2 results, eyes rare disease expansion

ANI Pharma delivered exceptional financial performance in Q2 2023, driven by strong revenue growth and record EBITDA.
The company's focus on rare diseases and generics, along with a solid financial position, positions it well for future growth.
ANI Pharma faces challenges in maintaining growth momentum and navigating industry competition but has opportunities for expansion.

ANI Pharma reports record Q3 revenues, raises full-year guidance

ANI Pharmaceuticals (ANIP) delivered impressive Q3 results with record revenues and substantial growth in key segments. Despite market challenges, the company's strategic investments and raised guidance signal confidence in future performance and expansion.

ANI Pharmaceuticals reports record 2023 earnings, eyes growth opportunities

ANI Pharmaceuticals delivered a stellar performance in Q4 2023, achieving record revenue and profitability figures, driven by strong sales in key product segments.
While the company faces challenges in maintaining growth rates and navigating market dynamics, ANI Pharmaceuticals is well-positioned to capitalize on opportunities for expansion and innovation.
With a solid financial foundation, diverse product portfolio, and strategic growth outlook for 2024, ANI Pharmaceuticals remains poised for continued success and market leadership in the pharmaceutical industry.

ANI Pharma reports strong Q1 earnings, eyes Rare Disease growth

ANI Pharma's Q1 2024 performance reflects robust revenue growth across key segments, supported by strategic initiatives and a focus on innovation.
While facing challenges in R&D spending variability and supply tailwinds, the company remains well-positioned to capitalize on growth opportunities.
Opportunities lie in expanding the Rare Disease business, exploring new specialties for Cortrophin Gel, and pursuing strategic M&A for sustained growth.
ANI Pharma's prudent approach to capital deployment and confidence in growth through acquisitions underscore a promising outlook for future expansion.

ANI Pharma reports record revenues, announces Alimera acquisition for growth

ANI Pharma delivered a strong Q2 2024 performance with record revenues and significant growth in key product segments.
The proposed acquisition of Alimera Sciences signals ANI's strategic expansion into high-growth commercial products, enhancing its market position.
While facing integration challenges, ANI's raised guidance and focus on accretive EPS from the acquisition highlight a positive outlook for future growth.

ANI Pharmaceuticals (ANIP) reports record Q3 revenues and eyes rare disease growth in 2025

ANI Pharmaceuticals (ANIP) delivered a robust Q3 performance with record revenues and raised full-year guidance, driven by strong growth in Cortrophin Gel and generics business. The company's emphasis on rare diseases and new offerings positions it for continued growth in 2025. While challenges exist in the payer landscape and acquisition integration, ANIP's strategic focus on key specialties offers promising opportunities for expansion.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

ANI Pharmaceuticals, Inc. is a bio-pharmaceutical company, which engages in the development, manufacture, and marketing of branded and generic prescription pharmaceuticals. It operates through the Generics, Established Brands, and Other, and Rare Disease segments. The Generics, Established Brands, and Other segment consists of contract manufactured products, development services, royalties, and other. The Rare Disease segment involves the operations related to Cortrophin Gel. The company was founded on August 29, 1996 and is headquartered in Baudette, MN.

BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced business highlights and financial results for the three and 12 months ended December 31, 2022. “2022 was a transformative year for ANI, taking us past critical inflection points for our two key growth drivers – the launch of Cortrophin Gel, our foundational Rare Disease asset, and investment in our generics business.

ANI Pharmaceuticals Reports Record Fourth Quarter Financial Results and Achieves Full Year 2022 Revenue Milestone; Initiates 2023 Guidance

ANI (ANIP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ANI Pharmaceuticals (ANIP) Earnings Expected to Grow: Should You Buy?

BRIDGEWATER, N.J.--(BUSINESS WIRE)-- #alembic--Cosette Pharmaceuticals, Inc. ("Cosette") has obtained the US marketing rights to Betaine Anhydrous for Oral Solution 180gm (“Betaine”) in an agreement with ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) and commenced shipping (NDC #0713-0352-81) to customers this week.

Cosette Pharmaceuticals Launches Betaine Anhydrous Powder, AB-rated to Cystadane® (betaine anhydrous for oral solution)

BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced that the Company will release its fourth quarter and full year 2022 financial results on Thursday, March 9, 2023, prior to market open. Nikhil Lalwani, President and Chief Executive Officer, and Stephen P. Carey, Senior Vice President, Finance, and Chief Financial Officer, will host a conference call to discuss the results as follows: Date Thursday, March 9, 2023 Time 8:30 a.m.

ANI Pharmaceuticals to Discuss Fourth Quarter and Full Year 2022 Financial Results on March 9, 2023, at 8:30 a.m. ET

AbbVie

Results from three major testosterone trials expected in 2023, including the largest testosterone cardiovascular safety/efficacy trials for men and women. AbbVie led Androgel 1.62% 5,246-participant cardiovascular safety trial is also measuring efficacy for dysthymia, clinical fractures, anemia, and progression from pre-diabetes to diabetes, results could lead to sNDA submissions.

2023 A Big Year For Testosterone: AbbVie And ANI Pharmaceuticals Best Positioned To Benefit

BAUDETTE, Minn.--( BUSINESS WIRE )--ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that it received U.S. Food and Drug Administration (FDA) approval for the Abbreviated New Drug Application (ANDA) for Levocarnitine Tablets USP, 330 mg.

ANI Pharmaceuticals Announces the FDA Approval and Launch of Levocarnitine Tablets USP

BAUDETTE, Minn.--( BUSINESS WIRE )--ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that the Company received U.S. Food and Drug Administration (FDA) approval for the Abbreviated New Drug Application (ANDA) for Fluoxetine Oral Solution, USP 20 mg/5 mL.

ANI Pharmaceuticals Announces the FDA Approval and Launch of Fluoxetine Oral Solution USP

BAUDETTE, Minn.--( BUSINESS WIRE )--ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that it received U.S. Food and Drug Administration (FDA) approval for the Abbreviated New Drug Application (ANDA) for Trimethoprim Tablets USP, 100 mg.

ANI Pharmaceuticals Announces the FDA Approval and Launch of Trimethoprim Tablets USP

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP ) Q3 2022 Earnings Conference Call November 9, 2022 8:00 AM ET Company Participants Judy DiClemente - IR Nikhil Lalwani - President and CEO Steve Carey - CFO Christopher Mutz - Head, Rare Disease Conference Call Participants Elliot Wilbur - Raymond James Brandon Folkes - Cantor Fitzgerald Greg Fraser - Truist Securities Operator Good morning, everyone. My name is Todd, and I'll be your conference operator.

ANI Pharmaceuticals, Inc. (ANIP) Q3 2022 Earnings Call Transcript

ANI (ANIP) delivered earnings and revenue surprises of 10.34% and 6.49%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

ANI Pharmaceuticals (ANIP) Surpasses Q3 Earnings and Revenue Estimates

ANI Pharmaceuticals Reports Third Quarter 2022 Financial Results; Reports Record Net Revenues

ANI Pharmaceuticals to Discuss Third Quarter 2022 Financial Results on November 9, 2022, at 8:00 a.m. ET

BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (“ANI” or the “Company”) today announced that Krista L. Davis will join the Company as Chief Human Resources Officer, effective September 12. Ms. Davis brings to the Company over 20 years of executive leadership experience in human resources, talent management, and organizational development. “Ms. Davis is an important addition to our leadership team and will bring strategic and innovative thought leadership to our prior

ANI Pharmaceuticals Appoints Krista Davis as Chief Human Resources Officer

BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc. (“ANI” or “the Company”) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, and Stephen Carey, Chief Financial Officer, will present at the H.C. Wainwright 24th Annual Global Investment Conference as follows: Date:   Monday, September 12, 2022 Time:   12:30PM ET Webcast:   Click Here The webcast will be accessible via the Company's website at www.anipharmaceuticals.com, in the Investors section under Events an

ANI Pharmaceuticals to Present at the H.C. Wainwright 24th Annual Global Investment Conference

BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced the launch of Prochlorperazine Maleate Tablets USP, 5 mg and 10 mg. ANI's Prochlorperazine Maleate Tablets USP, 5 mg and 10 mg are the generic version of the Reference Listed Drug (RLD) Compazine® and were developed in technical collaboration with Biophore India Pharmaceuticals Pvt. Ltd. (“Biophore”). The current annual U.S. market for Prochlorperazine Maleate Tablets USP, 5 mg an

ANI Pharmaceuticals Announces the Launch of Prochlorperazine Maleate Tablets USP

BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that the Company received U.S. Food and Drug Administration (FDA) approval for the Abbreviated New Drug Application (ANDA) for Dexamethasone Tablets USP 1.5mg, 4mg and 6mg. ANI's Dexamethasone Tablets USP 1.5mg, 4mg and 6mg are the generic version of the Reference Listed Drug (RLD) Decadron®. The current annual U.S. market for Dexamethasone Tablets USP 1.5mg, 4mg and 6mg is approximat

ANI Pharmaceuticals Announces FDA Approval and Imminent Launch of Dexamethasone Tablets USP

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP ) Q2 2022 Earnings Conference Call August 8, 2022 8:00 AM ET Company Participants Lisa Wilson - Investor Relations Nikhil Lalwani - President & Chief Executive Officer Steve Carey - Chief Financial Officer, Senior Vice President of Finance & Corporate Secretary Conference Call Participants Elliot Wilbur - Raymond James Greg Fraser - Truist Securities Brandon Folkes - Cantor Fitzgerald Operator Good day everyone and welcome to today's ANI Pharmaceuticals, Inc. Second Quarter 2022 Earnings Results Call. [Operator Instructions] Please note, this call may be recorded.

ANI Pharmaceuticals, Inc. (ANIP) CEO Nikhil Lalwani on Q2 2022 Results - Earnings Call Transcript

BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced business highlights and financial results for the three and six months ended June 30, 2022. “Second quarter net revenues of $73.9 million represent a new quarterly record for the Company, driven by the first full quarter of Purified Cortrophin Gel sales and growth in generic pharmaceuticals revenues. We continue to see acceleration in the number of patients treated with Cortrophin. We

ANI Pharmaceuticals Reports Second Quarter 2022 Financial Results; Reports Record Net Revenues and Raises Full-Year 2022 Net Revenue Guidance for Purified Cortrophin® Gel

ANI Pharmaceuticals (ANIP) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Should You Buy ANI Pharmaceuticals (ANIP) Ahead of Earnings?

BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced the launch of Acebutolol Hydrochloride Capsules. ANI's Acebutolol Hydrochloride Capsules are the generic version of the Reference Listed Drug (RLD) Sectral®. The current annual U.S. market for Acebutolol Hydrochloride Capsules is approximately $10.0 million, according to IQVIA/IMS Health, a leading healthcare data and analytics provider. "We are pleased to announce the launch and

ANI Pharmaceuticals Announces the Launch of Acebutolol Hydrochloride Capsules USP

ANI (ANIP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ANI Pharmaceuticals (ANIP) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the purchase of four abbreviated new drug applications (ANDAs) from Oakrum Pharma, LLC, a privately owned biopharmaceutical company. “We are pleased to expand our generics product portfolio with the acquisition of four limited competition ANDAs. We expect to launch these products and see the value unlock in 2023. This transaction bears further testament to ANI's strength in business d

ANI Pharmaceuticals Acquires ANDAs from Oakrum Pharma, LLC

BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced that the Company will release its second quarter 2022 financial results on Monday, August 8, 2022, prior to market open. Nikhil Lalwani, President and Chief Executive Officer, and Stephen P. Carey, Senior Vice President, Finance, and Chief Financial Officer, will host a conference call to discuss the results as follows: Date   Monday, August 8, 2022 Time   8:00 a.m. ET Toll free (

ANI Pharmaceuticals to Discuss Second Quarter 2022 Financial Results on August 8, 2022, at 8:00 a.m. ET

BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced that Meredith W. Cook will join the Company as SVP, General Counsel and Corporate Secretary, effective July 18. Ms. Cook brings over 20 years of legal and leadership experience in specialty and generics pharmaceuticals, including in corporate governance, mergers and acquisitions (M&A), strategic transactions, and intellectual property (IP). “We are delighted to welcome Ms. Cook to

ANI Pharmaceuticals Appoints Meredith W. Cook as SVP, General Counsel and Corporate Secretary

ANI (ANIP) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

News for ANI Pharma Stock (ANIP)